 Patients receive belinostat intravenously IV over 30-90 minutes once daily QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 orally PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission CR, complete remission with incomplete blood count recovery CRi, cytogenetic complete remission CRc, or molecular complete remission CRm who do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response. 